Femasys Inc. Overview
Pro stress-test →Femasys Inc. is a biomedical company focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The company offers FemaSeed (intratubal insemination solution), FemVue (companion diagnostic for fallopian tube assessment), FemCerv (endocervical tissue sampler), and FemBloc (non-surgical permanent birth control solution).
Strategic Profile
Pro stress-test →Femasys is expanding its European commercial footprint through distribution agreements and has expanded market entry in Spain, France, Switzerland and the Benelux region. The company achieved FDA IDE approval and FDA 510(k) clearance for next-generation FemVue device, with commercial progress including financing with potential proceeds up to $58 million.
Competitive Landscape
Pro stress-test →Femasys competes in the women's reproductive health and fertility treatment space. Main competitors include Navrogo (NVRO), Options for Infertility (OFIX), and other medical device manufacturers serving fertility and women's health. Femasys positions itself as offering innovative, accessible, in-office solutions for both fertility treatment and non-surgical permanent contraception, differentiating through its FemBloc first-of-its-kind permanent birth control technology.
Industry Context
Femasys Inc. operates in Medical Devices - Women's Reproductive Health & Fertility.
Key facts
Founded: 2004 · Headquarters: Suwanee, Georgia, US · Employees: 70 · Revenue: $1.63M (2024) · Market cap: $34.73M